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Abstract
Objectives: Validated or standardized self-report questionnaires used in research studies and
clinical evaluation of chronic fatigue syndrome (CFS) generally focus on the assessment of fatigue.
There are relatively few published questionnaires that evaluate case defining and other
accompanying symptoms in CFS. This paper introduces the self-report CDC CFS Symptom
Inventory and analyzes its psychometric properties.
Methods: One hundred sixty-four subjects (with CFS, other fatiguing illnesses and non fatigued
controls) identified from the general population of Wichita, Kansas were enrolled. Evaluation
included a physical examination, a standardized psychiatric interview, three previously validated
self-report questionnaires measuring fatigue and illness impact (Medical Outcomes Survey Short-
Form-36 [MOS SF-36], Multidimensional Fatigue Inventory [MFI], Chalder Fatigue Scale), and the
CDC CFS Symptom Inventory. Based on theoretical assumptions and statistical analyses, we
developed several different Symptom Inventory scores and evaluated them on their ability to
differentiate between participants with CFS and non-fatigued controls.
Results: The Symptom Inventory had good internal consistency and excellent convergent validity.
A Total score (all symptoms), Case Definition score (CFS case defining symptoms) and Short Form
score (6 symptoms with minimal correlation) differentiated CFS cases from controls. Furthermore,
both the Case Definition and Short Form scores distinguished people with CFS from fatigued
subjects who did not meet criteria for CFS.
Conclusion: The Symptom Inventory appears to be a reliable and valid instrument to assess
symptoms that accompany CFS. It is a positive addition to existing instruments measuring fatigue
because it allows other dimensions of the illness to be assessed. Further research is needed to
confirm and replicate the current findings in a normative population.
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1. Background
Chronic fatigue syndrome (CFS) is an incapacitating ill-
ness defined by disabling chronic fatigue and characteris-
tic accompanying symptoms [1]. CFS has no confirmatory
physical signs or characteristic laboratory abnormalities
and its etiology and pathophysiology remain unknown
[2]. Many of the problems searching for markers of CFS
reflect ambiguities of definition. Recently, an International
CFS Study Group identified areas of vagueness in the case
definition and proposed revisions in its utilization [3].
The  Group  recommended that validated standardized
instruments be used to evaluate the functional impair-
ment, fatigue, and accompanying symptoms associated
with CFS. They recommended that future research utilize
the Medical Outcomes Survey Short-Form-36 (SF-36) [4]
to assess functional impairment and that the Checklist
Individual Strength (CIS) [5] or Multidimensional Fatigue
Inventory (MFI) [6] be used to measure general dimen-
sions of fatigue. The Group was unaware of standardized
and validated instruments that assessed the CFS symptom
complex and suggested that investigators consider using a
symptom checklist developed by the US Centers for Dis-
ease Control and Prevention (CDC) for use in popula-
tion-based surveys. The CDC Symptom Inventory assesses
the full range of CFS associated symptoms, has been used
in several population-based studies (i.e., comparative
data are available), and is publicly available. However, the
Symptom Inventory has not been formally validated. The
objective of the present study was to validate the Symp-
tom Inventory as a questionnaire for evaluation of CFS
associated symptoms.
Methods
Study design/subjects
This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services
and the Helsinki Declaration. The CDC Human Subjects
committee approved study protocols. All participants
were volunteers who gave informed consent.
This study enrolled subjects who had previously partici-
pated in the 1997 through 2000 Wichita CFS Surveillance
Study [7,8]. In brief, the Surveillance Study used a random-
digit-dialing telephone survey to screen 56,146 adult resi-
dents (18 to 69 years of age) of Wichita, Kansas. A surveil-
lance cohort of 3,528 adults who reported fatigue of at
least 1-month duration and 3,634 non-fatigued persons
completed a detailed telephone interview and eligible
subjects were clinically evaluated to assess CFS. A subset of
the cohort was followed at 12-, 24-and 36-months with a
telephone interview and clinical evaluation. Fatigued par-
ticipants in the present study were a subset of the 659
fatigued adults identified during surveillance who were
classified as CFS by 1994 research case definition criteria
[1] or unexplained chronic fatigue not meeting criteria for
CFS (ISF). Non-fatigued controls were randomly selected
from the cohort who participated in all telephone inter-
views at baseline, 12-, 24-, and 36-month follow-up peri-
ods, who had never reported fatigue of at least 1-month
duration, and who had never been identified with medi-
cal or psychiatric conditions exclusionary for CFS.
Clinical Measurements
People who agreed to participate were admitted to a
Wichita hospital research unit for 2-days. Upon arrival,
they provided a standardized past medical history, a
review of current medications; they then underwent a
brief standardized physical examination and standardized
psychiatric evaluation of Axis I disorders (DIS) [9] that
exclude classification of CFS (melancholic major depres-
sion, bipolar disorder, psychosis, substance abuse, eating
disorders) [1,3]. We also collected blood and urine for
routine analysis, including: a complete blood count with
differential, C-reactive protein, alanine aminotransferase,
albumin, alkaline phosphatase, aspartate aminotrans-
ferase, total bilirubin, calcium, carbon dioxide, chloride,
creatinine, glucose, potassium, total protein, sodium, urea
nitrogen BUN, pregnancy test, TSH, free T-4, and urinaly-
sis. In addition they completed the CDC Symptom Inven-
tory and 3 well standardized and validated self-
administered questionnaires (described below). Subjects
were classified based on results of laboratory, physical and
psychologic examination, fatigue and symptoms at the
time of the study as: CFS (currently meeting the 1994 CFS
research case definition) [1]; ISF (currently unexplained
fatigue but not meeting CFS criteria); remission (prior CFS
or ISF but currently not fatigued); never fatigued (non-
fatigued controls); or, excluded (missing data, laboratory
or psychological abnormalities).
The Medical Outcomes Survey Short-Form (SF-36) [4]
(QualityMetric Incorporated, Lincoln, Rhode Island)
assesses function and well-being in 8 areas: 1) limitations
in physical activities because of health problems; 2) limi-
tations in social activities because of physical or emo-
tional problems; 3) limitations in usual role activities
because of physical health problems; 4) bodily pain; 5)
general mental health; 6) limitations in usual role activi-
ties because of emotional problems; 7) vitality (energy
and fatigue); and 8) general health perceptions. Scores in
each area reflect ability to function (higher values being
better).
The Multidimensional Fatigue Inventory (MFI) [6] is a 20-
item self-report instrument that measures 5 dimensions of
fatigue; General Fatigue, Physical Fatigue, Mental Fatigue,
Reduced Motivation and Reduced Activity. The score in
each dimension reflects severity of fatigue (higher values
being worse). The MFI has been primarily used to measure
fatigue in cancer patients [10].Population Health Metrics 2005, 3:8 http://www.pophealthmetrics.com/content/3/1/8
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The Chalder Fatigue Scale (Chalder) [11] includes 10
questions measuring physical and mental fatigue. We
added 2 questions regarding muscle pain: "Do your mus-
cles hurt at rest?" and "Do your muscles hurt after
exercise?".
CDC CFS Symptom Inventory
The Symptom Inventory collects information about the
presence, frequency, and intensity of 19 fatigue and ill-
ness-related symptoms during the month preceding the
interview; these include all 8 CFS-defining symptoms
(post-exertional fatigue, unrefreshing sleep, problems
remembering or concentrating, muscle aches and pains,
joint pain, sore throat, tender lymph nodes and swollen
glands, and headaches). It also catalogues diarrhea, fever,
chills, sleeping problems, nausea, stomach or abdominal
pain, sinus or nasal problems, shortness of breath, sensi-
tivity to light, and depression. Perceived frequency of each
symptom was rated on a four-point scale (1 = a little of the
time, 2 = some of the time, 3 = most of time, 4 = all of the
time), and severity or intensity of symptoms was meas-
ured on a three-point scale (1 = mild, 2 = moderate, 3 =
severe).
Symptom Inventory Scoring
To summarize the degree of distress associated with each
symptom, individual symptom scores were calculated by
multiplying the frequency score by the intensity score. We
transformed the intensity scores into equidistant scores
before multiplication (i.e., 0 = symptom not reported 1 =
mild, 2.5 = moderate, 4 = severe) resulting in range 0–16
for each symptom. We calculated a Total score for each
person by summing the 19 individual symptom scores
(possible range from 0 to 304). We also defined a Case
Definition score as the sum of the 8 individual CFS case-
definition symptom scores and an Other Symptoms score
by considering only the 11 non-CFS symptoms.
Short Form of the CDC Symptom Inventory
We also explored the possibility of deriving a shorter ver-
sion of the Symptom Inventory that would be a reliable
and economic screening instrument. We created a Short
Form of the Symptom Inventory by consecutively elimi-
nating those symptoms whose scores had a corrected
item-total score correlation < 0.60. The Short Form
retained 6 symptoms: unusual fatigue after exertion, unre-
freshing sleep, muscle aches, sleeping problems, prob-
lems with memory, and problems with concentration.
Statistical Analyses
To evaluate the internal consistency of the MFI and the
Symptom inventory, we performed reliability analyses
based on the model of averaging the inter-item correla-
tion. Pearson's correlation coefficients between the CDC
Symptom Inventory, MFI, Chalder Fatigue Scale and SF-
36 were determined to evaluate convergent validity. We
assessed construct validity by using one-way analyses of
variance and Bonferroni post-hoc group comparisons to
compare the CDC Symptom Inventory scores across the
fatigue groups. We compared the Short and Total Forms
with respect to psychometric properties (i.e., internal con-
sistency and validity). The practicability of both scores
was compared with three more intuitive scores derived
from the Symptom Inventory; sum of all 19 individual fre-
quency scores (Frequency Score), sum of all 19 individual
intensity scores (Intensity Score), and the number of
reported symptoms.
Results
Two hundred twenty-seven people participated in the 2-
day clinical evaluation and participation rates (64 to
78%) were similar among the categories (p = .26). Five of
the 227 were excluded because of incomplete psychiatric
interviews, 29 because of exclusionary medical condi-
tions, 3 because of psychiatric conditions, and 26 because
of current major depression disorder with melancholic
features, resulting in 164 subjects for analysis. Twenty-
four subjects with prior fatigue (7 CFS and 17 ISF) were
classified as in remission. There were no differences in age,
body mass index, or sex between the classification groups
(Table 1).
Reliability analyses
Reliability analyses revealed good internal consistency for
the reduced motivation subscale of the MFI and excellent
internal consistency for the other four subscales. Cron-
Table 1: Characteristics by subject classification (N = 164). BMI is body mass index, CFS includes subjects with chronic fatigue 
syndrome, ISF includes those with unexplained chronic fatigue not meeting criteria for CFS, and NF are never fatigued controls
N Women (%) Age (Mean ± SD) BMI (Mean ± SD)
Classification
CFS 52 44 (84.6%) 49.9 ± 7.9 28.4 ± 5.1
ISF 40 29 (72.5%) 49.7 ± 9.3 28.7 ± 4.7
Remission 24 17 (70.8%) 51.2 ± 9.1 28.8 ± 5.1
Never Fatigued 48 41 (85.4%) 50.3 ± 8.5 28.9 ± 5.1Population Health Metrics 2005, 3:8 http://www.pophealthmetrics.com/content/3/1/8
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bach's alpha coefficients were 0.89 for general fatigue,
0.82 for physical fatigue, 0.90 for reduced activity, 0.77 for
reduced motivation, and 0.92 for mental fatigue. These
findings are similar to those of Smets and colleagues [6].
The Symptom Inventory Total score also reflected excel-
lent internal consistency, with a Cronbach's alpha coeffi-
cient of 0.88: Cronbach's alpha was 0.87 for the Symptom
Inventory Short-Form. Table 2 shows the corrected item-
total correlations (product terms) of all symptoms for the
Total score and Short Form. In addition, reliability analy-
ses revealed a Cronbach's alpha of 0.82 for the Case Defi-
nition score and 0.74 for the Other Symptoms score.
Table 3 shows the descriptive data for the Total, Case Def-
inition, Short Form, and the Other Symptoms scores.
Validity
Convergent validity of Symptom Inventory
The Total, Case Definition and Short Form scores all had
good convergent validity as determined by correlations
with the MFI, Chalder Fatigue Scale, and SF-36 subscales
(Table 4). As expected, high scores on the Symptom
Inventory correlated with high fatigue scores and low lev-
els of function. In other words, subjects who scored high
on questionnaires assessing fatigue and low on those
assessing functioning and well being, generally had high
Symptom Inventory scores.
Construct validity
The extent to which Symptom Inventory scores discrimi-
nate between subgroups classified as to fatigue status (e.g.,
CFS versus not fatigued or CFS versus ISF, CFS versus
remission) is one measure of the Inventory's practicability
for assessing fatiguing illnesses. All Bonferroni post-hoc
comparisons between never fatigued controls and those
classified as CFS or ISF showed significant mean differ-
ences related to Symptom Inventory scores (Figures 1 and
2). Also, those classified as in remission had significantly
lower symptom impact than those with CFS or ISF. The
Total score and the Case Definition score distinguished
between subjects classified CFS or ISF (Bonferroni post-
hoc test; p < .05), while the Symptom Inventory Short
Form revealed only a trend towards higher symptom
impact for the CFS. Subjects classified as CFS and ISF were
similar with respect to the Frequency score, the Intensity
score, and number of symptoms.
Discussion
This study showed that the CDC CFS Symptom Inventory
is a reliable and valid instrument for assessing symptoms
associated with CFS. Many studies conducted in tertiary
care settings have used ad hoc (non-validated) question-
naires to assess the frequency or intensity of CFS-defining
symptoms. In addition to lack of validation, one unan-
swered question from such studies concerns what is worse
– a severe symptom that occurs sporadically or a clinically
minimal symptom occurring every day. The Symptom
Inventory obviates this problem because it is scored as a
product-term of intensity and frequency and better repre-
sents the variance of each symptom.
Both the Total and the Case Definition scores effectively
assessed initial study classification as CFS, ISF, and never
fatigued. They also showed excellent psychometric prop-
erties, including good internal consistency and validity.
One might question the possibility of circular logic –
defining an illness by its symptoms then assessing psycho-
metric properties of a scale that measures the same symp-
toms. Unfortunately, as yet, CFS has no confirmatory
physical signs or characteristic laboratory abnormalities
[2]; so, in lieu of a 'gold standard', it is defined by disa-
Table 2: Corrected item to total correlations for the Symptom 
Inventory Total Score and the Symptom Inventory Short-Form 
Score
Symptom Corrected item to total 
correlations
Total score Short-form 
score
Sore throat .43
Tender nodes .48
Diarrhea .37
Unusual fatigue after exertion .69 .64
Muscle aches .70 .64
Joint pain .54
Feverishness .28
Chills .52
Unrefreshing sleep .77 .79
Sleeping problems .65 .70
Headaches .43
Memory problems .62 .66
Concentration .59 .67
Nausea .40
Stomach pain .32
Sinus problems .51
Shortness of breath .41
Sensitivity to light .41
Depression .52
Table 3: Descriptive data of the CDC Symptom Inventory 
Scores
CDC Symptom 
Inventory Scores
Mean SD Min Max
Total 36.22 33.87 0 153.50
Short-form 19.51 20.01 0 96
CDC Case definition 21.21 21.54 0 102
Other symptoms 15.02 14.11 0 62Population Health Metrics 2005, 3:8 http://www.pophealthmetrics.com/content/3/1/8
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bling chronic fatigue and characteristic accompanying
symptoms [1,3]. For initial classification in this study, we
defined CFS by literally applying criteria of the 1994 case
definition [1]. We classified subjects as CFS who stated
that they had been fatigued for at least 6-months; that the
fatigue severely affected their occupational, educational,
social, or recreational activities; who endorsed the
presence of at least 4 CFS defining symptoms; and, who
had no exclusionary medical or psychiatric conditions.
Subjects who had medically/psychiatrically unexplained
chronic fatigue not fulfilling all these criteria were consid-
ered ISF. This operational classification notwithstanding,
CFS represents a multi-faceted illness. Fatigue is a complex
construct and we employed 2 standardized and validated
instruments (the MFI and Chalder Fatigue Scale) to evalu-
ate its various dimensions (e.g., physical fatigue, mental
fatigue). Similarly, the impairment associated with CFS is
not unidimensional; so we utilized the SF-36 to quantify
the 8 major dimensions of function and wellbeing.
Finally, CFS includes a characteristic symptom complex
and we used the Symptom Inventory to evaluate the
intensity and frequency of accompanying symptoms. The
Total, Case Definition, and Short Form scores all had
good convergent validity as determined by correlations
with the 3 multidimensional measures of fatigue and
impairment. The Symptom Inventory scores also discrim-
inated between subgroups originally classified as CFS, ISF
or not fatigued and this is a measure of the instrument's
practicability for assessing fatiguing illness.
As noted above, there is no objective test to unequivocally
diagnose CFS so it is premature to evaluate sensitivity or
specificity of the various Symptom Inventory scores.
Rather, our objective was to evaluate the Inventory's psy-
chometric properties as baseline for its use in future stud-
ies. Studies of the clinical characteristics of CFS and other
unexplained fatiguing illnesses should utilize the
Symptom Inventory in conjunction with other instru-
ments that assess different dimensions and consequences
of fatigue (e.g., the MFI, SF-36) [3,10]. Beside the Symp-
tom Inventory Total and the Case Definition scores, the
Symptom Inventory Short Form score, consisting of only
6 symptoms (unusual fatigue after exertion, unrefreshing
sleep, muscle aches, sleeping problems, memory and con-
centration problems), appears to be an economic and pre-
cise screening measurement for the current status of
fatiguing illnesses.
The Symptom Inventory includes 10 symptoms that are
not used to define CFS. Although not considered in the
case definition, these symptoms are commonly reported
by chronically ill people and have proven useful for strat-
ification during analysis of descriptive and case control
studies. In addition, the International CFS Study Group rec-
Table 4: Pearson's correlation matrix of CDC Symptom Inventory scores and MFI, Chalder Fatigue Scale, and SF-36 subscales (N = 
164)
Total score Short-form Case definition score
Questionnaires r P r P r P
MFI
General fatigue .64 < .001 .67 < .001 .63 < .001
Physical fatigue .60 < .001 .62 < .001 .62 < .001
Reduced activity .60 < .001 .62 < .001 .57 < .001
Reduced motivation .53 < .001 .53 < .001 .50 < .001
Mental fatigue .54 < .001 .56 < .001 .54 < .001
Chalder Fatigue Scale .74 < .001 .76 < .001 .75 < .001
SF-36
Physical functioning -.58 < .001 -.56 < .001 -.60 < .001
Role-physical -.64 < .001 -.56 < .001 -.62 < .001
Bodily pain -.67 < .001 -.56 < .001 -.68 < .001
General health -.59 < .001 -.59 < .001 -.60 < .001
Vitality -.68 < .001 -.69 < .001 -.67 < .001
Social functioning -.66 < .001 -.62 < .001 -.63 < .001
Role-emotional -.39 < .001 -.40 < .001 -.37 < .001
Mental health -.46 < .001 -.48 < .001 -. 41 < .001
CDC Symptom Inventory Scores
Total .94 < .001 .97 < .001
Short-form .94 < .001 .95 < .001Population Health Metrics 2005, 3:8 http://www.pophealthmetrics.com/content/3/1/8
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ommended additional research to further develop the CFS
case definition and such research must assess a compre-
hensive range of symptoms. Finally, analytic studies of
CFS must consider somatization disorders (both as con-
founders and comorbid conditions); the full range of
symptoms in the Inventory is needed to categorize such
disorders.
At least one important limitation must be considered.
Although study subjects were recruited from the
community and do not reflect the strong biases inherent
of clinic patient populations, they did not represent the
general population; rather they comprised a sample of
people with and without unexplained fatiguing illnesses.
Thus, the excellent psychometric properties of the Symp-
tom Inventory cannot be generalized to the general
population. To further validate and evaluate the Symptom
Inventory, additional testing in a larger population-based
sample not stratified by fatigue is required. There is also a
need to determine the test-retest-reliability and stability of
the Symptom Inventory. The present study provides pre-
liminary results to encourage researchers to administer the
Symptom Inventory along with other standardized ques-
tionnaires measuring fatigue and functional impairment
in studies of CFS and other fatiguing illnesses.
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Mean scores for Symptom Inventory by subject classification Figure 1
Mean scores for Symptom Inventory by subject classification. All post-hoc comparisons between never fatigued and 
CFS or ISF were significant (at least: p < 0.05). All post-hoc comparisons between Remission and CFS or ISF were significant (at 
least: p < 0.05).
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